NCT05889195

Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria

Validation of Cxbladder Detect-Plus for the Detection of Urothelial Carcinoma in Subjects With Microscopic Hematuria (microDRIVE)
Pacific Edge Limited·ClinicalTrials.gov·diagnostic testNot yet recruiting
View on ClinicalTrials.gov
Study focus
Disease/Condition
Urothelial Carcinoma
Drug/Device/Intervention
Cxbladder urine test
Study type
Observational
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Pacific Edge Limited
Location
Durham, United States of America
Timeline & enrollment
Phase
N/A
Start date
Sep 01, 2023
End date
Apr 01, 2024
Enrollment
1000 participants
Primary outcome

The alignment of Cxbladder Detect-plus results with the standard of care diagnostic result for the presence or absence of UC, to validate Cxbladder Detect-plus performance in subjects with microscopic hematuria.

Summary

It is of current debate whether the use of invasive (referring to a process that requires
 insertion into the body) standard of care procedures such as a cystoscopy which is a
 procedure to look inside the bladder using a thin camera called a cystoscope, is appropriate
 for use in patients with microscopic hematuria or blood in urine invisible to the naked eye.
 This is because the risk of disease (bladder cancer - urothelial carcinoma) is relatively low
 in this population group, approximately 3%. Invasive procedures such as a cystoscopy comes
 with anxiety and pain, in addition to other potential side effects. This has resulted in low
 admittance in urology clinics for cystoscopy with hematuria (blood in urine) patients.
 Therefore, there is a need for a more simple, non-invasive test that can accurately detect
 the presence or absence of disease (urothelial carcinoma) in patients with microscopic
 hematuria. There is a potential role Cxbladder, a non-invasive, urine based test, can fill
 this role.

ICD-10 classifications
Carcinoma in situ: Other and unspecified urinary organsMalignant neoplasm of ureterMalignant neoplasms of urinary tractMalignant neoplasm: Overlapping lesion of urinary organsMalignant neoplasm: Urethra
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05889195
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05889195 through Pure Global AI's free database. This phase not specified trial is sponsored by Pacific Edge Limited and is currently Not yet recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 1000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.